var data={"title":"Vigabatrin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vigabatrin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7150?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vigabatrin-drug-information\" class=\"drug drug_general\">see &quot;Vigabatrin: Drug information&quot;</a> and <a href=\"topic.htm?path=vigabatrin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vigabatrin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238848\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Permanent vision loss:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Vigabatrin can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, vigabatrin also can damage the central retina and may decrease visual acuity.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The onset of vision loss from vigabatrin is unpredictable and can occur within weeks of starting treatment or sooner, or at any time during treatment, even after months or years.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Symptoms of vision loss from vigabatrin are unlikely to be recognized by the patients or caregivers before vision loss is severe. Vision loss of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Vision assessment is recommended at baseline (no later than 4 weeks after starting vigabatrin) and at least every 3 months during therapy, and about 3 to 6 months after the discontinuation of therapy. Once detected, vision loss caused by vigabatrin is not reversible. It is expected that, even with frequent monitoring, some patients will develop severe vision loss.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Consider drug discontinuation, balancing benefit and risk, if vision loss is documented.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Risk of new or worsening vision loss continues as long as vigabatrin is used. It is possible that vision loss can worsen despite discontinuing vigabatrin.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risk of vision loss, withdraw vigabatrin from patients who do not show substantial clinical benefit within 3 months of initiation for patients with refractory complex partial seizures and within 2 to 4 weeks of initiation for patients with infantile spasms, or sooner if treatment failure becomes obvious. Periodically reassess patient response to and continued need for vigabatrin.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not use vigabatrin in patients with, or at high risk of, other types of irreversible vision loss unless the benefits of treatment clearly outweigh the risks.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not use vigabatrin with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use the lowest dosage and shortest exposure to vigabatrin that is consistent with clinical objectives.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risk of permanent vision loss, vigabatrin is available only through a special restricted program under a risk evaluation and mitigation strategy (REMS) called the Vigabatrin REMS program. Further information is available at http://www.vigabatrinREMS.com or by calling 1-866-244-8175.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107369\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Sabril</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234016\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sabril</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042182\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Infantile Spasms, Treatment</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042214\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vigabatrin-drug-information\" class=\"drug drug_general\">see &quot;Vigabatrin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note: </b>Use the lowest effective and shortest exposure consistent with therapeutic objectives.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Infantile spasms:</b> Infants and Children 1 month to 2 years of age: Oral: Powder for oral solution: Initial: 50 mg/kg/day divided twice daily; may titrate upwards by 25 to 50 mg/kg/day increments every 3 days based on response and tolerability; maximum daily dose: 150 mg/kg/<b>day</b> divided twice daily; <b>Note:</b> To taper, decrease dose by 25 to 50 mg/kg/day every 3 to 4 days. Withdraw therapy in 2 to 4 weeks if a substantial clinical benefit is not observed or discontinue treatment if evidence of treatment failure becomes obvious earlier than 2 to 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Refractory complex partial seizures; adjunctive treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Children &ge;10 years and Adolescents: Dose dependent upon weight and/or age. Withdraw therapy if a substantial clinical benefit is not observed within 3 months of treatment initiation; discontinue therapy if evidence of treatment failure becomes obvious earlier than 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight 25 to 60 kg and age 10 to 16 years: Initial: 250 mg twice daily; increase daily dose in 500 mg increments at weekly intervals based on response and tolerability. Recommended maintenance dose: 1,000 mg twice daily; <b>Note</b>: To taper, decrease daily dose by one-third every week for 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &gt;60 kg (regardless of age), or age &gt;16 years (regardless of weight): Initial: 500 mg twice daily; increase daily dose in 500 mg increments at weekly intervals based on response and tolerability. Recommended dose: 1,500 mg twice daily. <b>Note:</b> To taper, decrease dose by 1000 mg daily on a weekly basis.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Limited data available: Children weighing &ge;10 <b>kg</b> and Adolescents &le;16 years: Initial: 40 mg/kg/day divided twice daily; maintenance dosages based on patient weight (Camposano 2008; Coppola 2004; Sabril prescribing information (Canada) 2012; Willmore 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">10 to 15 kg: 500 to 1,000 mg/day divided twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">16 to 30 kg: 1,000 to 1,500 mg/day divided twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">31 to 50 kg: 1,500 to 3,000 mg/day divided twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;50 kg: 2,000 to 3,000 mg/day divided twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Refractory complex partial seizures; adjunctive treatment:</b> Oral: Initial: 500 mg twice daily; increase daily dose by 500 mg increments at weekly intervals based on response and tolerability; recommended maintenance dose: 1500 mg twice daily; <b>Note: </b>To taper, decrease dose by 1,000 mg/day on a weekly basis. Withdraw therapy if a substantial clinical benefit is not observed within 3 months of treatment initiation; discontinue therapy if evidence of treatment failure becomes obvious earlier than 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &le;2 years: There are no dosage adjustment provided in US manufacturer's labeling; data is not available; vigabatrin is primarily eliminated through the kidney; use with caution; consider dosage reduction in patients with any degree of renal impairment (Sabril prescribing information [Canada] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;2 to &lt;10 years: Limited data available: patients with any degree of renal impairment should have dosage reduction (Sabril prescribing information [Canada] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;10 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;80 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 to 80 mL/minute: Decrease dose by 25%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;30 to 50 mL/minute: Decrease dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;10 to 30 mL/minute: Decrease dose by 75%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Reduces vigabatrin plasma concentration by 40% to 60%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; has not been studied; however, does not undergo appreciable hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233994\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sabril: 500 mg (50 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea, 50 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sabril: 500 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233980\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8104264\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020427s016,022006s018lbl.pdf#page%20=26&amp;token=Cdsc8OV4/jhvDonsTE3A+pLkpnXZyVa/fD65hm+6ARSYi9bgPJzriAro57uB1Ni6heI80Dl2vfw2XKFAtG3ugQvURmBVUhT7eMX6fxX54BrYcyou8Evy0pt6U+C5FSyR&amp;TOPIC_ID=13101\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020427s016,022006s018lbl.pdf#page =26</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042220\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered without regard to food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder for oral solution: Reconstitute powder packet prior to administration. The appropriate dose aliquot should be administered immediately after reconstitution; may use provided oral syringe. Any remaining liquid should be discarded. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133422\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234011\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042183\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monotherapy for treatment of infantile spasms in patients for whom the potential benefits outweigh the potential risk of vision loss (FDA approved in ages 1 month to 2 years) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adjunct therapy for refractory complex partial seizures in patients with inadequate response to several alternative treatments and for whom the potential benefits outweigh the potential risk of vision loss (FDA approved in ages &ge;10 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8308547\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vigabatrin may be confused with Vibativ</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234058\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adult and pediatric information is combined unless significantly different.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal behavior, abnormality in thinking, aggressive behavior, anxiety, ataxia, confusion, depression, disturbance in attention, dizziness, drowsiness (more common in infants), dysarthria, fatigue, headache, hyperreflexia, hypoesthesia, hyporeflexia, hypotonia (infants), impaired consciousness, insomnia (infants), irritability (more common in infants), lethargy, memory impairment, paresthesia, sedation (more common in infants), seizure (infants), sensory disturbance, status epilepticus, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (infants)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Fluid retention, increased thirst, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, abdominal pain, constipation, decreased appetite (infants), diarrhea, dyspepsia, hemorrhoids, increased appetite, nausea, viral gastroenteritis (infants), vomiting (more common in infants)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysmenorrhea, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Bruise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Candidiasis (infants), influenza, viral infection (infants)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, joint swelling, limb pain, myalgia, muscle spasm, shoulder pain, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Asthenopia, blurred vision, conjunctivitis, diplopia, nystagmus, strabismus, visual field loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis media (infants), tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis (infants), cough, croup (infants), dyspnea, nasal congestion (infants), pharyngitis, pharyngolaryngeal pain, pneumonia (infants), sinus headache, sinusitis (infants), upper respiratory tract infection (more common in infants)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (more common in infants)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute psychosis, angioedema, brain disease, cholestasis, deafness, delirium, facial edema, gastrointestinal hemorrhage, hypomania, laryngeal edema, malignant hyperthermia, multi-organ failure, optic neuritis, pruritus, psychosis, pulmonary embolism, respiratory failure, sexual disorder (delayed puberty), Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233999\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling: </i>Hypersensitivity to vigabatrin or any component of the formulation; pregnancy; breast-feeding </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233983\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anemia: Use has been associated with decreased hemoglobin and hematocrit; cases of significantly reduced hemoglobin (&lt;8 g/dL) and/or hematocrit (&lt;24%) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Edema: Peripheral edema and edema independent of hypertension, heart failure, weight gain, renal or hepatic dysfunction has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Patients must be closely monitored for potential neurotoxicity (observed in animal models but not established in adults).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: Peripheral neuropathy manifesting as numbness or tingling in the toes or feet, reduced distal lower limb vibration or position sensation, or progressive loss of reflexes, starting at the ankles, has been reported in adult patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vision loss: <b>[US Boxed Warning]: Vigabatrin causes permanent vision loss in infants, children, and adults. Due to the risk of vision loss and because vigabatrin, provides an observable symptomatic benefit when it is effective, the patient who fails to show substantial clinical benefit within a short period of time after initiation of treatment (2 to 4 weeks for infantile spasms; &lt;3 months for refractory complex partial seizures), should be withdrawn from therapy. If in the clinical judgment of the prescriber evidence of treatment failure becomes obvious earlier in treatment, vigabatrin should be discontinued at that time. Patient response to and continued need for treatment should be periodically assessed. The onset of vision loss is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time during treatment, even after months or years. The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss. It is possible that vision loss can worsen despite discontinuation. Assessment of vision loss is difficult in children and the frequency and extent of vision loss in infants and children is poorly characterized. Most data are available in adult patients. Vigabatrin causes permanent bilateral concentric visual field constriction in &gt;30% of patients ranging in severity from mild to severe, including tunnel vision to within 10 degrees of visual fixation, and can result in disability. In some cases, vigabatrin can damage the central retina and may decrease visual acuity. Symptoms of vision loss are unlikely to be recognized by the patient or caregiver before loss is severe. Vision loss of milder severity, although potentially unrecognized by the patient or caregiver, may still adversely affect function. Vision should be assessed to the extent possible at baseline (no later than 4 weeks after initiation), at least every 3 months during therapy and at 3 to 6 months after discontinuation. Once detected, vision loss is not reversible; even with frequent monitoring, it is expected that some patients will develop severe vision loss. In patients who cannot be tested, treatment may continue according to clinical judgement, with appropriate patient counseling. Vigabatrin should not be used in patients with, or at high risk of, other types of irreversible vision loss unless the benefits of treatment clearly outweigh the risks. The interaction of other types of irreversible vision damage with vision damage from vigabatrin has not been well-characterized, but is likely adverse. Vigabatrin should not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks. The lowest dose and shortest exposure should be used that is consistent with clinical objectives. The possibility that vision loss from vigabatrin may be more common, more severe or have more severe functional consequences in infants and children than in adults cannot be excluded.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Use has been associated with an average weight gain of 3.5 kg in adults and &ge;7% of baseline body weight in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric behavior: Use with caution in patients with a history of psychosis (psychotic/agitated reactions may occur more frequently), depression, or behavioral problems.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; modify dose in children (&ge;10 years) and adults with renal impairment (CrCl &lt;80 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: May cause an increase in seizure frequency in some patients; use with particular caution in patients with myoclonic seizures, which may be more prone to this effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly as moderate to severe sedation and confusion have been reported; consider dose and/or frequency adjustments as renal clearance may be decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Vigabatrin is not indicated as a first-line agent for complex partial seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; MRI abnormalities: Abnormal MRI changes have been reported in some infants. Resolution of MRI changes usually occurs with discontinuation of therapy. MRI changes were not seen in older children and adult patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; REMS program: Because of the risk of permanent vision loss, vigabatrin is only available through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) program. Under the Vigabatrin REMS program, only prescribers and pharmacies registered with the program are able to prescribe and distribute vigabatrin. Vigabatrin may only be dispensed to patients who are enrolled in and meet all conditions of the Vigabatrin REMS program. Call 866-244-8175 or visit http://www.vigabatrinREMS.com for further information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819291\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Dose dependent, asymptomatic MRI abnormalities have been reported in infants treated with vigabatrin for infantile spasms; resolution of abnormalities generally occurs upon vigabatrin discontinuation; abnormalities resolved in a few infants, despite continued use; some infants displayed coincident motor abnormalities, but no causal relationship has been established; risk for long-term clinical sequelae has not been studied. Animal models have shown intramyelinic edema in the brain; current evidence suggests that this does not occur in humans; however, patients should be monitored for neurotoxicity. A relationship between MRI abnormalities in infants and animal model findings has not been established. Somnolence and fatigue occurs at a higher incidence in infants compared to adults (infants: &le;45%; adults: &le;24%). May cause fever; higher incidence reported in infants than adults (&le;30% vs 6%). May cause vomiting; higher incidence in infants (up to 20%). Infants may experience a higher frequency of other adverse effects than adults, including vomiting and upper respiratory tract infections. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300217\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233987\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13101&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ClonazePAM: Vigabatrin may enhance the CNS depressant effect of ClonazePAM. Vigabatrin may increase the serum concentration of ClonazePAM. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Vigabatrin may decrease the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Vigabatrin may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233989\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234002\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Vigabatrin crosses the placenta in humans (Tran 1998). Birth defects have been reported following use in pregnancy and include: cardiac defects, limb defects, male genital malformations, fetal anticonvulsant syndrome, renal and ear abnormalities. Time of exposure or maternal dosage was not reported and information is not available relating to the incidence or types of these outcomes in comparison to the general epilepsy population. Visual field examinations have been conducted following in utero exposure in a limited number of children tested at &ge;6 years of age; no visual field loss was observed in 4 children and results were inconclusive in 2 others (Lawthorn 2009; Sorri 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Data collection to monitor pregnancy and infant outcomes following exposure to vigabatrin is ongoing. Healthcare providers are encouraged to enroll women exposed to vigabatrin during pregnancy in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042222\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Ophthalmologic examination by an ophthalmic professional with expertise in visual field interpretation and the ability to perform dilated indirect ophthalmoscopy of the retina at baseline (no later than 4 weeks after therapy initiation), periodically during therapy (every 3 months), and 3 to 6 months after discontinuation of therapy; assessment should include visual acuity and visual field whenever possible including mydriatic peripheral fundus examination and visual field perimetry, preferably by automated threshold visual field testing. Observe patient for excessive sedation, especially when instituting or increasing therapy; frequency, duration, and severity of seizure episodes; hemoglobin and hematocrit; renal function; weight; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes), neurotoxicity, peripheral neuropathy, and edema.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9837874\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">A correlation between serum concentrations and efficacy has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233982\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Irreversibly inhibits gamma-aminobutyric acid transaminase (GABA-T), increasing the levels of the inhibitory compound gamma amino butyric acid (GABA) within the brain. Duration of effect is dependent upon rate of GABA-T resynthesis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233998\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> A correlation between serum concentrations and efficacy has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration (rate of GABA-T resynthesis dependent): Variable (not strictly correlated to serum concentrations)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid, complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 1.1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Insignificant</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Tablet and oral solution are bioequivalent.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Prolonged in renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants (5 months to 2 years): ~5.7 hours; Children (4 to 14 years): ~5.5 hours (Sabril Canadian product monograph 2015); Children (10 to 16 years): 9.5 hours; Adults: 10.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Infants (5 months to 2 years): 2.5 hours; Children (10 to 16 years) and Adults: 1 hour (2 hours with food)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80%, as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Infants: 2.4 &plusmn; 0.8 L/hour; Children: 5.7 &plusmn; 2.5 L/hour; Adults: 7 L/hour </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324087\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Sabril Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $7,977.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Vigabatrin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $130.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sabril Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $15,954.58</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234004\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Sabril (AE, AR, AT, AU, BB, BE, BH, BR, CH, CL, CO, CR, CU, CY, CZ, DE, DO, EG, FR, GB, GR, GT, HK, HN, HR, HU, IE, IT, JO, JP, KR, KW, LB, LT, LU, MT, NI, NL, NZ, PA, PL, PT, PY, QA, SA, SG, SI, SK, SV, TH, TR, TW, UY, VN, ZA);</li>\n      <li>Sabrilan (IL);</li>\n      <li>Sabrilex (DK, ES, FI, IS, NO, SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bar-Oz B, Nulman I, Koren G, et al, &ldquo;Anticonvulsants and Breast-Feeding: A Critical Review,&rdquo; <i>Paediatr Drugs</i>, 2000, 2(2):113-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/abstract-text/10937463/pubmed\" target=\"_blank\" id=\"10937463\">10937463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Camposano SE, Major P, Halpern E, et al, &quot;Vigabatrin in the Treatment of Childhood Epilepsy: A Retrospective Chart Review of Efficacy and Safety Profile,&quot; <i>Epilepsia</i>, 2008, 49(7):1186-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/abstract-text/18479386/pubmed\" target=\"_blank\" id=\"18479386\">18479386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Challier JC, Rey E, Bintein T, et al, &quot;Passage of S(+) and R(-) Gamma-Vinyl-GABA Across the Human Isolated Perfused Placenta,&quot; <i>Br J Clin Pharmacol</i>, 1992, 34(2):139-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/abstract-text/1419475/pubmed\" target=\"_blank\" id=\"1419475\">1419475</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coppola G, &quot;Treatment of Partial Seizures in Childhood: An Overview,&quot; <i>CNS Drugs</i>, 2004, 18(3):133-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/abstract-text/14871158/pubmed\" target=\"_blank\" id=\"14871158\">14871158</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lawthom C, Smith PE, and Wild JM, &quot;<i>In utero</i> Exposure to Vigabatrin: No Indication of Visual Field Loss,&quot; <i>Epilepsia</i>, 2009, 50(2):318-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/abstract-text/18616557/pubmed\" target=\"_blank\" id=\"18616557\">18616557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mackay MT, Weiss SK, Adams-Webber T, et al, &quot;Practice Parameter: Medical Treatment of Infantile Spasms: Report of the American Academy of Neurology and the Child Neurology Society,&quot; <i>Neurology</i>, 2004, 62(10):1668-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/abstract-text/15159460/pubmed\" target=\"_blank\" id=\"15159460\">15159460</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearl PL, Vezina LG, Saneto RP, et al, &quot;Cerebral MRI Abnormalities Associated With Vigabatrin Therapy,&quot; <i>Epilepsia</i>, 2009, 50(2):184-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/abstract-text/18783433/pubmed\" target=\"_blank\" id=\"18783433\">18783433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sabril (vigabatrin) [prescribing information]. Deerfield, IL: Lundbeck; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sabril (vigabatrin) [prescribing information]. Laval, Quebec: Aventis Pharma Inc; August 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sorri I, Herrg&aring;rd E, Viinikainen K, et al, &quot;Ophthalmologic and Neurologic Findings in Two Children Exposed to Vigabatrin <i>in utero</i>,&quot; <i>Epilepsy Res</i>, 2005, 65(1-2):117-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/abstract-text/15941649/pubmed\" target=\"_blank\" id=\"15941649\">15941649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tran A, O'Mahoney T, Rey E, et al, &quot;Vigabatrin: Placental Transfer <i>in vivo</i> and Excretion Into Breast Milk of the Enantiomers,&quot; <i>Br J Clin Pharmacol</i>, 1998, 45(4):409-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/abstract-text/9578192/pubmed\" target=\"_blank\" id=\"9578192\">9578192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheless JW, Carmant L, Bebin M, et al, &quot;Magnetic Resonance Imaging Abnormalities Associated With Vigabatrin in Patients With Epilepsy,&quot; <i>Epilepsia</i>, 2009, 50(2):195-205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/abstract-text/19054414/pubmed\" target=\"_blank\" id=\"19054414\">19054414</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Willmore LJ, Abelson MB, Ben-Menachem E, et al, &quot;Vigabatrin: 2008 Update,&quot; <i>Epilepsia</i>, 2009, 50(2):163-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/abstract-text/19230067/pubmed\" target=\"_blank\" id=\"19230067\">19230067</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13101 Version 155.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F11238848\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8107369\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F234016\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1042182\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1042214\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F233994\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F233980\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8104264\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1042220\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133422\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F234011\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1042183\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8308547\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F234058\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F233999\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F233983\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819291\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300217\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F233987\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F233989\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F234002\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1042222\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F9837874\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F233982\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F233998\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324087\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F234004\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13101|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vigabatrin-drug-information\" class=\"drug drug_general\">Vigabatrin: Drug information</a></li><li><a href=\"topic.htm?path=vigabatrin-patient-drug-information\" class=\"drug drug_patient\">Vigabatrin: Patient drug information</a></li></ul></div></div>","javascript":null}